Proteus Syndrome

^{Three Comparative Hand Sculptures Representing Tissue Overgrowth and Mosaic Structure in Proteus Syndrome (Generated by Artificial Intelligence).}" image-element-format="right" image-height="896" image-source="https://cdn.t3pedia.org/media/uploads/2026/03/13/yjshmDowVvwJSq7ZXx3t1KWvEBMqvq0D.jpg" image-width="1200">

Proteus syndrome is a mosaic genetic disorder characterized by asymmetric, disproportionate, and progressive overgrowth of various tissues. This syndrome affects the skeletal system, skin, adipose tissue, and central nervous system. The disease typically presents at birth with no symptoms or only mild findings and progresses during infancy and early childhood, leading to structural deformities in tissues. Growth abnormalities exhibit a patchy distribution across the body.

History and Nomenclature

The disease was first described as a distinct clinical entity in 1979^【1】. The name was assigned in 1983, and the term "Proteus syndrome" was coined in reference to Proteus, the sea god of Greek mythology known for his ability to change shape^【2】. Joseph Carey Merrick, who lived in 19th-century England and was known as the "Elephant Man," is one of the most recognized historical and cultural examples of this condition^【3】.

Prevalence

Proteus syndrome is classified as a rare disease in medical literature. Since its description, approximately 200 to 250 confirmed cases have been reported worldwide, with an estimated 120 of these patients currently alive.^【4】 The genetic basis of the disorder—a postzygotic somatic mutation occurring during embryogenesis and not inherited from parents—prevents its transmission across generations and is the primary reason for its low case incidence.

Genetic Basis and Etiology

The cellular basis of Proteus syndrome lies in a somatic mutation occurring in a subset of cells during embryonic development. This mutation is caused by the c.49G>A (p.Glu17Lys) variant in the AKT1 gene^【5】. This mutation leads to constitutive activation of the PI3K/AKT/mTOR signaling pathway, which regulates cell proliferation and survival. Because the mutation does not affect germ cells and arises after embryogenesis, the disorder is not inherited from parents to offspring.

Clinical Signs and Findings

The clinical presentation varies among individuals and progresses over time. Asymmetric and disproportionate overgrowth is observed throughout the body.

Skeletal System and Bone Growth

Skeletal abnormalities include gigantism of the extremities (arms, legs, hands, and feet) and cranial anomalies (macrocephaly). The bone overgrowth caused by the syndrome is irregular and calcified. Asymmetric macrodactyly (excessive digit growth) is commonly observed.

Skin and Subcutaneous Tissue Findings

Cutaneous manifestations include cerebriform connective tissue nevus (CCTN). Analysis of clinical reports indicates that these lesions appear on the soles of the feet in 80% of patients and on the palms in 20%^【6】. These lesions consist of grooved connective tissue resembling the convolutions of the brain. Patients also frequently exhibit epidermal nevi and vascular malformations of capillary, venous, or lymphatic origin.

Adipose Tissue Abnormalities

The syndrome causes regional variations in adipose tissue distribution. Some areas of the body develop lipomas and fat accumulations, while other regions in the same patient show failure of adipose tissue development (lipohipoplasia).

class=\

Vascular Anomalies and Thromboembolic Complications

In Proteus syndrome, vascular malformations of capillary, venous, and lymphatic origin are observed. During the course of the disease, deep vein thrombosis (DVT) and pulmonary thromboembolism (PE) may develop. DVT is characterized by slowed blood flow and clot formation in the deep veins of the legs. Pulmonary thromboembolism occurs when these clots travel through the bloodstream and obstruct the pulmonary arteries, increasing pressure on the right ventricle of the heart and leading to respiratory and circulatory failure.

Tumor Susceptibility and Neoplastic Development

The persistent activation of the cell proliferation signaling pathway increases the risk of neoplasia and tumor formation. Reported neoplastic lesions in patients include bilateral ovarian cystadenomas, monomorphic adenomas of the parotid gland, testicular tumors, and meningiomas^【7】. These neoplastic growths also follow the mosaic distribution pattern of the syndrome and develop regionally.

Neurological, Pulmonary, and Visceral Findings

Neurological Findings

In some patients, neuromotor and cognitive development remains within normal limits. However, structural brain malformations such as hemimegalencephaly—where one cerebral hemisphere is abnormally enlarged—have been reported, along with intellectual disability and epileptic seizures^【8】.

Pulmonary and Visceral Findings

Respiratory abnormalities include cystic or bullous lung changes. Disorganized growth also affects internal organs, leading to asymmetric enlargement or cystic formations in the kidneys, spleen, and tonsils^【9】.

Diagnostic Criteria and Medical Evaluation

The diagnosis of Proteus syndrome is based on a combination of clinical findings and genetic testing results.

General and Specific Criteria

To suspect the diagnosis, all three general criteria must be met: mosaic distribution of lesions, sporadic occurrence, and progressive nature of findings. In individuals meeting these general criteria, clinical evaluation involves scoring specific signs categorized as A, B, and C. Category A includes cerebriform connective tissue nevus (CCTN); categories B and C include asymmetric overgrowth, tumors, and vascular malformations. For a definitive diagnosis, individuals with a confirmed AKT1 mutation must score at least 10 points on the specific criteria; those without a detected mutation must score at least 15 points^【10】.

Molecular Confirmation

Following clinical assessment, diagnosis is confirmed by molecular testing at the cellular level. Genetic analysis of biopsy samples from affected tissues must detect the c.49G>A (p.Glu17Lys) mutation in the AKT1 gene to complete the diagnostic process^【11】. Because mutant cells are rarely detectable in blood samples, genetic testing must be performed directly on affected lesion tissues.

Differential Diagnosis

Other syndromes presenting with asymmetric overgrowth and tissue anomalies resemble Proteus syndrome clinically. The leading condition in differential diagnosis is the PIK3CA-Related Overgrowth Spectrum (PROS). CLOVES syndrome, which falls under the PROS umbrella and is characterized by congenital lipomatous overgrowth, vascular malformations, and skeletal anomalies, must be considered. Although both syndromes arise from defects in the PI3K/AKT/mTOR pathway, they are distinguished by the mutated gene: PIK3CA in PROS, rather than AKT1.

Other conditions excluded in differential diagnosis include Bannayan-Zonana syndrome, caused by mutations in the PTEN gene; Klippel-Trenaunay syndrome, marked by vascular malformations; and isolated hemihyperplasia.

Treatment and Management Approaches

There is currently no curative treatment for Proteus syndrome. Management requires a multidisciplinary approach involving orthopedics, dermatology, genetics, and surgery.

Surgical Interventions and Orthopedic Management

Orthopedic surgery is used to control asymmetric growth and deformities of the skeletal system. Epiphysiodesis (closure of growth plates) and corrective surgeries are preferred to address limb length discrepancies, scoliosis, or macrodactyly. Local mass excisions and liposuction are employed for skin and adipose tissue overgrowth; however, postoperative recurrence of tumor-like structures and hypertrophic scarring are common. Airway deformities and vascular anomalies increase the risks associated with anesthesia during surgical procedures.

Targeted Medical Therapies

The pan-AKT inhibitor miransertib (MK-7075), administered orally and targeting the PI3K/AKT/mTOR pathway, has been included in clinical trials to halt tissue overgrowth. Phase 1/2 MOSAIC clinical trials are evaluating the safety profile of miransertib. In these trials, the initial dose is 15 mg/m² daily for the first three 28-day cycles, followed by 25 mg/m² daily^【12】. For PROS caused by mutations at a different step in the same biological pathway, alpelisib-containing medications have been approved for clinical use.

Complication Prevention and Psychosocial Support

Prophylactic anticoagulant therapy is administered before and after surgical interventions to reduce the risk of deep vein thrombosis and pulmonary embolism. Strengthening patient communication and improving health literacy among caregivers through public media campaigns to ensure accurate information dissemination are supportive measures in medical management.

Prognosis

The prognosis in Proteus syndrome varies depending on the distribution of mutant cells and the tissues affected. Clinical reports indicate a life expectancy ranging from 9 months to 29 years^【13】. Major causes of death include severe neurological involvement, progressive respiratory failure, and pulmonary thromboembolism.

Warning: The content in this article is provided solely for general encyclopedic informational purposes. The information here should not be used for diagnosis, treatment, or medical advice. Always consult a physician or qualified healthcare professional before making any health-related decisions. The author and KÜRE Digital Encyclopedia assume no responsibility for any consequences arising from the use of this information for diagnostic or therapeutic purposes.